Atropine does not inhibit late asthmatic responses induced by toluene-diisocyanate in sensitized subjects. 1987

P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
Second Medical Clinic, University of Pisa, Pisa, Italy.

To determine whether early and/or late asthmatic responses induced by toluene diisocyanate (TDI) are caused by a reflex mechanism involving stimulation of muscarinic receptors, we studied the effect of the muscarinic antagonist atropine on early and late airway response induced by TDI. A preliminary study was conducted in asthmatics to assess whether the selected dose of atropine provided adequate muscarinic blockade. On different days we measured the provocation dose (in milligrams) of carbachol causing a 15% decrease in FEV1 (PD15FEV1) without and with atropine premedication (0.008 or 0.012 mg/kg subcutaneous atropine 30 or 90 min before carbachol challenge test). We found that 0.008 to 0.012 mg/kg subcutaneous atropine increased the PD15FEV1 carbachol by 6- to 10-fold, inducing a consistent and prolonged decrease in nonspecific bronchial hyperresponsiveness to cholinergic agent. Then we examined 10 subjects with a history of sensitization to TDI in 2 sets of experiments. In the first set of experiments, we studied the subjects before and after exposure to TDI (0.04 ppm; 30 min) after no treatment. In the second set of experiments, carried out 1 to 2 wk later, we repeated the same procedure after treatment with atropine (0.008 to 0.012 mg/kg atropine sulfate administered subcutaneously 30 min before TDI challenge, and then at 90-min intervals after TDI exposure); all patients showed symptoms of atropine effect (dryness of mouth, cycloplegia, increased heart rate).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009784 Occupational Diseases Diseases caused by factors involved in one's employment. Diseases, Occupational,Occupational Illnesses,Disease, Occupational,Illnesse, Occupational,Illnesses, Occupational,Occupational Disease,Occupational Illnesse
D002217 Carbachol A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS. Carbamylcholine,Carbacholine,Carbamann,Carbamoylcholine,Carbastat,Carbocholine,Carboptic,Doryl,Isopto Carbachol,Jestryl,Miostat,Carbachol, Isopto
D003485 Cyanates Organic salts of cyanic acid containing the -OCN radical. Cyanate
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
March 1989, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
September 1987, The Journal of allergy and clinical immunology,
P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
January 1987, Advances in prostaglandin, thromboxane, and leukotriene research,
P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
January 1991, Respiration; international review of thoracic diseases,
P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
May 1992, European journal of pharmacology,
P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
January 1990, Lung,
P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
November 1985, The American review of respiratory disease,
P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
October 1989, Annals of allergy,
P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
December 1987, The American review of respiratory disease,
P Paggiaro, and E Bacci, and D Talini, and F L Dente, and O Rossi, and N Pulerá, and L M Fabbri, and C Giuntini
March 1991, The American review of respiratory disease,
Copied contents to your clipboard!